IntrinsicIntrinsic
← All summaries

Churchill Capital Corp IX/Cayman

CCIX
Financials & Chart →

Business Summary

Churchill Capital Corp IX (the "Company") is a blank check company, also known as a Special Purpose Acquisition Company (SPAC), incorporated on December 18, 2023, in the Cayman Islands, with the sole purpose of effecting a Business Combination with one or more businesses or entities . The Company has not generated any operating revenues to date and does not expect to do so until it consummates its initial Business Combination . Its efforts have been limited to organizational activities, activities related to its Initial Public Offering (IPO), and searching for and consummating a Business Combination, including the PlusAI Business Combination . The Company's business model is centered on identifying and acquiring a target business, thereby providing an alternative to a traditional IPO for the target company .

The Company's core business model revolves around identifying and acquiring a private company to take public. It generates non-operating income from interest earned on funds held in a Trust Account . The primary customer segments are the shareholders of the target business, who exchange their shares for the Company's Class A Ordinary Shares or a combination of shares and cash . The Company aims to provide a more expeditious and cost-effective method for a target business to become public compared to a typical IPO .

The Company has no product or service lines as it is a blank check company with no operations . Its activities are focused on the process of identifying, evaluating, and executing a Business Combination.

For the fiscal year ended December 31, 2025, the Company reported net income of $8,556,703 . This includes $12,494,752 of interest income earned on marketable securities and cash held in the Trust Account, offset by $3,938,049 of general and administrative costs. As of December 31, 2025, the Company had marketable securities and cash held in the Trust Account totaling $307,617,399 . Cash held outside the Trust Account was $2,469 . The Company had total current liabilities of $172,969 and a deferred underwriting fee payable of $10,062,500 . The Class A ordinary shares subject to possible redemption were valued at approximately $10.70 per share , totaling $307,617,399 . The Company reported a total shareholders' deficit of $(10,073,766) .

Comparing the fiscal year ended December 31, 2025, to December 31, 2024, net income decreased from $8,791,874 in 2024 to $8,556,703 in 2025. Interest income earned on marketable securities and cash held in the Trust Account increased from $9,622,647 in 2024 to $12,494,752 in 2025. However, general and administrative costs significantly increased from $830,773 in 2024 to $3,938,049 in 2025. Cash held outside the Trust Account decreased substantially from $2,412,564 in 2024 to $2,469 in 2025. The redemption value per Public Share increased from approximately $10.30 in 2024 to approximately $10.70 in 2025.

During the reported period, the Company entered into the PlusAI Merger Agreement on June 5, 2025, with Plus Automation, Inc. ("PlusAI") and its Merger Subs, intending to effect a Business Combination . This agreement was amended twice: on September 8, 2025, to clarify the exchange of PlusAI Common Stock from options into SPAC Class B Common Stock , and on September 18, 2025, to remove the closing condition requiring $100 million in Available Closing SPAC Cash . The PlusAI Registration Statement was declared effective on January 12, 2026 . On January 13, 2026, the Company borrowed $250,000 against the WCL Promissory Note, with $1,250,000 remaining available for withdrawal . The extraordinary general meeting (EGM) to approve the PlusAI Business Combination was rescheduled from February 3, 2026, to February 11, 2026, to allow more time for shareholder engagement following PlusAI's expanded partnership with TRATON Group . The Company also adopted ASU 2025-03 on July 1, 2025, which impacts the accounting for the PlusAI Business Combination .

Business Outlook

The Company's primary objective for the upcoming period is to consummate the PlusAI Business Combination . The PlusAI Registration Statement was declared effective on January 12, 2026 , and the extraordinary general meeting of shareholders to approve the proposed Business Combination has been rescheduled to February 11, 2026 . The closing of the PlusAI Business Combination is subject to several conditions, including shareholder approvals from both the Company and PlusAI, the expiration or termination of the Hart-Scott-Rodino waiting period, no governmental order preventing the combination, the Company having at least $5,000,001 of net tangible assets at closing, and the SPAC Class A Common Stock being listed on Nasdaq . A key condition for PlusAI is that the cash available in the Trust Account (after redemptions and before transaction expenses) plus net proceeds from any incremental financing must be at least $100,000,000 at closing .

The main growth area for the Company is the successful completion of the PlusAI Business Combination. PlusAI is described as an identified target business, and the Company believes its Management Team and M. Klein and Company are well-positioned to identify and execute attractive Business Combination opportunities . The Company expects to favor target companies with compelling long-term growth prospects, opportunities for valuation improvements, attractive competitive dynamics, consolidation opportunities, competitive advantages, significant potential for recurring revenue, opportunities for operational improvement, attractive steady-state margins, high incremental margins, and attractive free cash flow characteristics . The value of the aggregate consideration to be paid to PlusAI stockholders and vested equityholders at closing will be based on a pre-money equity value of PlusAI of $1,200,000,000 , subject to certain closing adjustments, including an increase by net proceeds from any bona fide equity financing transaction by PlusAI prior to closing . Additionally, during the five-year period following the Closing, up to 15,000,000 additional shares of SPAC Common Stock may be issued to eligible pre-Closing PlusAI security holders in three equal tranches of 5,000,000 shares each, contingent on certain price targets of SPAC Class A Common Stock .

Regarding operational outlook, the Company expects to incur increased expenses as a result of being a public company, including legal, financial reporting, accounting, and auditing compliance costs, as well as due diligence expenses . The Company's liquidity needs are a concern, as it currently lacks sufficient funds to sustain operations for at least one year from the financial statement issuance date . Management plans to address this by completing a Business Combination . The Company has Permitted Withdrawals from the Trust Account for working capital, limited to $1,000,000 annually from interest earned . For the year ended December 31, 2025, the Company withdrew $1,000,000 and has no further amounts available until May 6, 2026 .

For planned capital allocation, the Company intends to use substantially all funds in the Trust Account, including interest earned (net of taxes and excluding the Deferred Fee), to complete its Business Combination . If share capital or debt is used as consideration, remaining Trust Account proceeds will be used for working capital, other acquisitions, and growth strategies of the target business . The Underwriters are entitled to a Deferred Fee of $10,062,500 , payable only upon completion of the initial Business Combination . Additionally, an advisory fee of $7,000,000 is payable to Citigroup Global Markets Inc. upon consummation of the PlusAI Business Combination, with a potential additional fee of up to $3,000,000 at the discretion of the Company and PlusAI . Legal fees of approximately $3,420,000 have been incurred and are contingent upon the completion of a Business Combination, with a premium ranging from 50% to 100% of incurred fees to be paid at the Company's discretion . A due diligence fee of $1,050,000 was incurred, with $900,000 paid and $150,000 remaining contingent on customer satisfaction and Business Combination consummation . The Sponsor may provide Working Capital Loans up to $1,500,000 , convertible into WCL Conversion Units at $10.00 per unit . As of January 13, 2026, $250,000 has been borrowed against the WCL Promissory Note, with $1,250,000 remaining available .

Management has flagged several structural headwinds and execution risks. The Company's ability to complete its initial Business Combination, including the PlusAI Business Combination, within the Combination Period (by May 6, 2026, or August 6, 2026, if a definitive agreement is executed by May 6, 2026) is a significant concern . Failure to do so would result in liquidation and redemption of Public Shares . The Company may be unable to obtain additional financing needed for the Business Combination or to fund the target's operations and growth . The increasing number of SPACs may lead to scarcer attractive targets and increased competition, potentially raising acquisition costs or making targets less interested in SPAC mergers due to negative public perception . The Company's public securities' potential liquidity and trading are also a risk .

Geographic, regulatory, and macro factors identified as constraints include changes in laws or regulations, fluctuations in inflation and interest rates, military or other conflicts, and disruptions to equity or debt capital markets . If the PlusAI Business Combination involves a U.S. company, the U.S. federal 1% excise tax on stock repurchases could be imposed . If the Company effects a Business Combination with a foreign company, it would be subject to additional risks . The Company is a Cayman Islands exempted company and is subject to changing laws and regulations regarding regulatory matters, corporate governance, and public disclosure .

Risk Factors

The Company faces material risks, primarily stemming from its nature as a blank check company with no operating history and no revenues, creating a limited basis for shareholders to evaluate its ability to achieve its business objective of completing an initial Business Combination . A significant risk is the inability to complete the initial Business Combination, including the PlusAI Business Combination, within the Combination Period, which would lead to liquidation and redemption of Public Shares, with Warrants expiring worthless . The Company may struggle to obtain additional financing required for the Business Combination or to fund the operations and growth of a target business like PlusAI, potentially forcing restructuring or abandonment of the transaction . There is also a risk that the Company may issue Ordinary Shares to investors in connection with the Business Combination at a price below the prevailing market price, diluting existing shareholders . The increasing number of SPACs could intensify competition for attractive targets, raising acquisition costs or deterring targets due to negative public perception of SPAC mergers . Fluctuations in inflation and interest rates, as well as military or other conflicts and disruptions to capital markets, could impede the consummation of a Business Combination . Changes in laws or regulations, including the U.S. federal 1% excise tax on stock repurchases for U.S. target companies , or a failure to comply with them, could adversely affect the business . The availability of funds from interest income in the Trust Account for Permitted Withdrawals, limited to $1,000,000 annually, may be insufficient for operations prior to the Business Combination . Cybersecurity incidents or attacks could result in financial loss and impact the ability to consummate a Business Combination . The Company's status as a "controlled company" due to the Sponsor's voting rights for director appointments prior to a Business Combination means it may qualify for exemptions from certain Nasdaq corporate governance requirements, potentially reducing shareholder protections . The nominal purchase price paid by the Sponsor for Founder Shares (approximately $0.003 per share) could result in significant dilution to Public Shareholders upon Business Combination consummation, and the Sponsor may profit substantially even if Public Shareholders experience losses .

Management Priorities

Management's overall tone emphasizes the Company's strategic approach to identifying and executing attractive Business Combination opportunities, leveraging the experience of its Management Team, M. Klein and Company, and Strategic and Operating Partners . They highlight their capabilities in sourcing, structuring, acquiring, and selling businesses, fostering relationships, negotiating favorable terms, executing transactions across geographies and economic conditions, and accessing capital markets . The key strategic priorities are to complete the initial Business Combination, specifically the PlusAI Business Combination, by May 6, 2026 (or August 6, 2026, if a definitive agreement is executed by May 6, 2026) , and to select a high-quality target at an attractive valuation, negotiate favorable acquisition terms, and improve the operational performance of the acquired company . Management has explicitly stated that the extraordinary general meeting to approve the PlusAI Business Combination has been rescheduled to February 11, 2026 , to allow additional time for shareholder engagement following PlusAI's expanded partnership with TRATON Group . They also acknowledge the ongoing assessment of liquidity needs and the potential requirement for additional financing to complete the Business Combination .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Status as a Public Company
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 1, Business — Status as a Public Company
  7. [7] Item 1, Business — Status as a Public Company
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  13. [13] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  14. [14] Item 8, Consolidated Balance Sheets
  15. [15] Item 8, Consolidated Balance Sheets
  16. [16] Item 8, Consolidated Balance Sheets
  17. [17] Item 8, Consolidated Balance Sheets
  18. [18] Item 8, Consolidated Balance Sheets
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  26. [26] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  27. [27] Item 8, Consolidated Balance Sheets
  28. [28] Item 8, Consolidated Balance Sheets
  29. [29] Item 1, Business — PlusAI Business Combination
  30. [30] Item 1, Business — PlusAI Business Combination
  31. [31] Item 1, Business — PlusAI Business Combination
  32. [32] Item 1, Business — PlusAI Business Combination
  33. [33] Item 7, MD&A — Recent Developments
  34. [34] Item 7, MD&A — Recent Developments
  35. [35] Item 7, MD&A — Recent Developments
  36. [36] Item 7, MD&A — Recent Developments
  37. [37] Item 7, MD&A — Recent Developments
  38. [38] Item 7, MD&A — Recent Accounting Standards
  39. [39] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  40. [40] Item 7, MD&A — Recent Developments
  41. [41] Item 7, MD&A — Recent Developments
  42. [42] Item 1, Business — PlusAI Business Combination
  43. [43] Item 1, Business — PlusAI Business Combination
  44. [44] Item 1, Business — PlusAI Business Combination
  45. [45] Item 1, Business — PlusAI Business Combination
  46. [46] Item 1, Business — Management Team
  47. [47] Item 1, Business — Management Team
  48. [48] Item 1, Business — PlusAI Business Combination
  49. [49] Item 1, Business — PlusAI Business Combination
  50. [50] Item 1, Business — PlusAI Business Combination
  51. [51] Item 1, Business — PlusAI Business Combination
  52. [52] Item 1, Business — PlusAI Business Combination
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  55. [55] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  56. [56] Item 7, MD&A — Permitted Withdrawals
  57. [57] Item 7, MD&A — Permitted Withdrawals
  58. [58] Item 7, MD&A — Permitted Withdrawals
  59. [59] Item 7, MD&A — Permitted Withdrawals
  60. [60] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  61. [61] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  62. [62] Item 7, MD&A — Underwriting Agreement
  63. [63] Item 7, MD&A — Underwriting Agreement
  64. [64] Item 7, MD&A — Advisory Agreement
  65. [65] Item 7, MD&A — Advisory Agreement
  66. [66] Item 7, MD&A — Advisory Agreement
  67. [67] Item 7, MD&A — Legal and Due Diligence Fees
  68. [68] Item 7, MD&A — Legal and Due Diligence Fees
  69. [69] Item 7, MD&A — Legal and Due Diligence Fees
  70. [70] Item 7, MD&A — Legal and Due Diligence Fees
  71. [71] Item 7, MD&A — Legal and Due Diligence Fees
  72. [72] Item 7, MD&A — Legal and Due Diligence Fees
  73. [73] Item 7, MD&A — Legal and Due Diligence Fees
  74. [74] Item 7, MD&A — Working Capital Loans
  75. [75] Item 7, MD&A — Working Capital Loans
  76. [76] Item 7, MD&A — Recent Developments
  77. [77] Item 7, MD&A — Recent Developments
  78. [78] Item 7, MD&A — Recent Developments
  79. [79] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  80. [80] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  81. [81] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  82. [82] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  83. [83] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  84. [84] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  85. [85] Item 1A, Risk Factors — Risks Relating to Acquiring or Operating a Business in Foreign Countries
  86. [86] Item 1A, Risk Factors — Risks Relating to Acquiring or Operating a Business in Foreign Countries
  87. [87] Item 1A, Risk Factors — Risks Relating to Acquiring or Operating a Business in Foreign Countries
  88. [88] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  89. [89] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  90. [90] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  91. [91] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  92. [92] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  93. [93] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  94. [94] Item 1A, Risk Factors — Risks Relating to Acquiring or Operating a Business in Foreign Countries
  95. [95] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  96. [96] Item 7, MD&A — Permitted Withdrawals
  97. [97] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  98. [98] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  99. [99] Item 1A, Risk Factors — Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  100. [100] Item 1A, Risk Factors — Risks Relating to our Securities and Shareholder Rights
  101. [101] Item 1A, Risk Factors — Risks Relating to our Securities and Shareholder Rights
  102. [102] Item 1, Business — Management Team
  103. [103] Item 1, Business — Business Strategy
  104. [104] Item 1, Business — Initial Public Offering
  105. [105] Item 1, Business — Management Team
  106. [106] Item 7, MD&A — Recent Developments
  107. [107] Item 7, MD&A — Recent Developments
  108. [108] Item 7, MD&A — Liquidity, Capital Resources and Going Concern

Analysis on 5/20/2026